CA2835336A1 - Pharmaceutical combination comprising despro36 exendi-4(1-39)-lys6-nh2 and metformin for treating diabetes type 2 patients - Google Patents

Pharmaceutical combination comprising despro36 exendi-4(1-39)-lys6-nh2 and metformin for treating diabetes type 2 patients Download PDF

Info

Publication number
CA2835336A1
CA2835336A1 CA2835336A CA2835336A CA2835336A1 CA 2835336 A1 CA2835336 A1 CA 2835336A1 CA 2835336 A CA2835336 A CA 2835336A CA 2835336 A CA2835336 A CA 2835336A CA 2835336 A1 CA2835336 A1 CA 2835336A1
Authority
CA
Canada
Prior art keywords
injection
lixisenatide
morning
evening
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835336A
Other languages
English (en)
French (fr)
Inventor
Louise Silvestre
Gabor Boka
Patrick Miossec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2835336A1 publication Critical patent/CA2835336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2835336A 2011-05-13 2012-05-11 Pharmaceutical combination comprising despro36 exendi-4(1-39)-lys6-nh2 and metformin for treating diabetes type 2 patients Abandoned CA2835336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166052 2011-05-13
EP11166052.8 2011-05-13
PCT/EP2012/058779 WO2012156312A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in the treatment of diabetes type 2

Publications (1)

Publication Number Publication Date
CA2835336A1 true CA2835336A1 (en) 2012-11-22

Family

ID=46052773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835336A Abandoned CA2835336A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination comprising despro36 exendi-4(1-39)-lys6-nh2 and metformin for treating diabetes type 2 patients

Country Status (12)

Country Link
US (1) US20130040878A1 (enExample)
EP (1) EP2709652A1 (enExample)
JP (1) JP6005140B2 (enExample)
KR (1) KR20140041553A (enExample)
CN (2) CN103648519A (enExample)
AR (1) AR086356A1 (enExample)
AU (1) AU2012257780B2 (enExample)
BR (1) BR112013029256A8 (enExample)
CA (1) CA2835336A1 (enExample)
MX (1) MX356728B (enExample)
RU (2) RU2013155480A (enExample)
WO (1) WO2012156312A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SG10201704716XA (en) * 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP4130005A4 (en) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
CN115315426B (zh) 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
SI2324853T1 (sl) * 2009-11-13 2015-12-31 Sanofi-Aventis Deutschland Gmbh Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2

Also Published As

Publication number Publication date
MX356728B (es) 2018-06-12
RU2017129878A (ru) 2019-02-05
US20130040878A1 (en) 2013-02-14
JP6005140B2 (ja) 2016-10-12
RU2013155480A (ru) 2015-06-20
AR086356A1 (es) 2013-12-04
KR20140041553A (ko) 2014-04-04
JP2014518860A (ja) 2014-08-07
WO2012156312A1 (en) 2012-11-22
BR112013029256A8 (pt) 2018-01-16
AU2012257780B2 (en) 2017-06-01
EP2709652A1 (en) 2014-03-26
CN103648519A (zh) 2014-03-19
BR112013029256A2 (pt) 2016-11-29
CN109045283A (zh) 2018-12-21
MX2013013198A (es) 2014-02-20

Similar Documents

Publication Publication Date Title
AU2012257780B2 (en) Pharmaceutical combination for use in the treatment of diabetes type 2
AU2012257780A1 (en) Pharmaceutical combination for use in the treatment of diabetes type 2
US20250134964A1 (en) Method for inducing weight loss in a type 2 diabetes mellitus patient
AU2012213435B2 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20230028588A1 (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AU2012257847B2 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
AU2012234180B2 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
AU2012257847A1 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
EP2611458A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140411

FZDE Discontinued

Effective date: 20200831